Skip Navigation


Annals of Oncology Advance Access originally published online on February 2, 2005
Annals of Oncology 2005 16(3):513; doi:10.1093/annonc/mdi071
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/3/513    most recent
mdi071v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tripathy, D
Right arrow Search for Related Content
PubMed
Right arrow Articles by Tripathy, D
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Letter to the Editor

Reply to "Letter to the Editor on ‘Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial"’, by A. M. Westermann doi:10.1093/annonc/mdi072

The first 10% of the full text of this article appears below.

The original ibandronate trials were written and initiated before the approval and availability of bisphosphonates to prevent complications . . . [Full Text of this Article]

D Tripathy*

University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, NC8.106, Dallas, TX 75390-8852, USA

Email: debu.tripathy@utsouthwestern.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?